Novavax downgraded by JP Morgan with a new price target
$NVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $6.00 | Sell | Citigroup |
| 2/28/2025 | $19.00 | Buy | BTIG Research |
| 7/30/2024 | $8.00 | Neutral → Underweight | JP Morgan |
| 5/10/2024 | $4.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 5/10/2024 | Underweight → Neutral | JP Morgan | |
| 8/9/2023 | $15.00 | Neutral → Buy | B. Riley Securities |
| 4/20/2023 | $55.00 → $10.00 | Outperform → Market Perform | TD Cowen |
| 3/1/2023 | $29.00 → $10.00 | Buy → Neutral | B. Riley Securities |
Citigroup initiated coverage of Novavax with a rating of Sell and set a new price target of $6.00
BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00
JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00